201 related articles for article (PubMed ID: 37530894)
21. Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
Asken BM; VandeVrede L; Rojas JC; Fonseca C; Staffaroni AM; Elahi FM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Boxer AL; Miller BL; Rosen HJ; Kramer JH; Casaletto KB
J Int Neuropsychol Soc; 2022 Jul; 28(6):588-599. PubMed ID: 34158138
[TBL] [Abstract][Full Text] [Related]
22. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
[TBL] [Abstract][Full Text] [Related]
23. Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR Study.
Twait EL; Gerritsen L; Moonen JEF; Verberk IMW; Teunissen CE; Visser PJ; van der Flier WM; Geerlings MI;
J Am Heart Assoc; 2024 Feb; 13(4):e032134. PubMed ID: 38353228
[TBL] [Abstract][Full Text] [Related]
24. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
25. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.
Gill J; Latour L; Diaz-Arrastia R; Motamedi V; Turtzo C; Shahim P; Mondello S; DeVoto C; Veras E; Hanlon D; Song L; Jeromin A
Neurology; 2018 Oct; 91(15):e1385-e1389. PubMed ID: 30209234
[TBL] [Abstract][Full Text] [Related]
26. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
27. Burden of Dilated Perivascular Spaces, an Emerging Marker of Cerebral Small Vessel Disease, Is Highly Heritable.
Duperron MG; Tzourio C; Sargurupremraj M; Mazoyer B; Soumaré A; Schilling S; Amouyel P; Chauhan G; Zhu YC; Debette S
Stroke; 2018 Feb; 49(2):282-287. PubMed ID: 29311265
[TBL] [Abstract][Full Text] [Related]
28. Age-Specific Associations of Renal Impairment With Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease in Transient Ischemic Attack and Stroke.
Liu B; Lau KK; Li L; Lovelock C; Liu M; Kuker W; Rothwell PM
Stroke; 2018 Apr; 49(4):899-904. PubMed ID: 29523652
[TBL] [Abstract][Full Text] [Related]
29. Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study.
Low A; Prats-Sedano MA; McKiernan E; Carter SF; Stefaniak JD; Nannoni S; Su L; Dounavi ME; Muniz-Terrera G; Ritchie K; Lawlor B; Naci L; Malhotra P; Mackay C; Koychev I; Ritchie CW; Markus HS; O'Brien JT
Alzheimers Res Ther; 2022 Oct; 14(1):154. PubMed ID: 36224605
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
[TBL] [Abstract][Full Text] [Related]
32. Type 2 Diabetes, Change in Depressive Symptoms Over Time, and Cerebral Small Vessel Disease: Longitudinal Data of the AGES-Reykjavik Study.
Rensma SP; van Sloten TT; Ding J; Sigurdsson S; Stehouwer CDA; Gudnason V; Launer LJ
Diabetes Care; 2020 Aug; 43(8):1781-1787. PubMed ID: 32527799
[TBL] [Abstract][Full Text] [Related]
33. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
34. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
35. Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.
van Leijsen EMC; Kuiperij HB; Kersten I; Bergkamp MI; van Uden IWM; Vanderstichele H; Stoops E; Claassen JAHR; van Dijk EJ; de Leeuw FE; Verbeek MM
Stroke; 2018 Apr; 49(4):884-890. PubMed ID: 29540613
[TBL] [Abstract][Full Text] [Related]
36. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study.
van Sloten TT; Sigurdsson S; van Buchem MA; Phillips CL; Jonsson PV; Ding J; Schram MT; Harris TB; Gudnason V; Launer LJ
Am J Psychiatry; 2015 Jun; 172(6):570-8. PubMed ID: 25734354
[TBL] [Abstract][Full Text] [Related]
37. NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease.
Wilms AE; de Boer I; Pelzer N; In't Veld SGJG; Middelkoop HAM; Teunissen CE; Terwindt GM
J Neurol; 2024 Apr; ():. PubMed ID: 38581544
[TBL] [Abstract][Full Text] [Related]
38. Cerebral Small Vessel Disease Progression and the Risk of Dementia: A 14-Year Follow-Up Study.
Jacob MA; Cai M; van de Donk V; Bergkamp M; Marques J; Norris DG; Kessels RPC; Claassen JAHR; Duering M; Tuladhar AM; Leeuw FE
Am J Psychiatry; 2023 Jul; 180(7):508-518. PubMed ID: 37073486
[TBL] [Abstract][Full Text] [Related]
39. Understanding the relationship between type-2 diabetes, MRI markers of neurodegeneration and small vessel disease, and dementia risk: a mediation analysis.
Grasset L; Frison E; Helmer C; Catheline G; Chêne G; Dufouil C
Eur J Epidemiol; 2024 Apr; 39(4):409-417. PubMed ID: 38190014
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
